Krish Patel, MD

Allogeneic and in vivo CAR T therapies simplify manufacturing and delivery, potentially expanding access to cellular therapy beyond specialized centers.

Trispecific T-cell engagers target 2 tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.

CAR T and bispecific T-cell engagers move earlier in blood cancer care, reshaping sequencing and expanding access beyond academic centers.

Purpose-built, decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials aren’t just a last resort.

Next-gen T‑cell immunotherapies tackle resistance and expand access, as bispecifics, trispecifics, and off‑the‑shelf or in vivo CAR T-cell therapies move earlier.

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results.

Central Screening revolutionizes clinical trial enrollment by integrating technology and expertise, streamlining patient matching for targeted cancer therapies.

Krish Patel, MD, discusses the areas of research he finds particularly interesting for the treatment of patients with mantle cell lymphoma.

Kris Patel, MD, discusses the real-world data for treatment with ibrutinib in patients with relapsed/refractory mantle cell lymphoma as compared to clinical trials.